Abstract 3870
Background
The incidence of BCBM is increasing as a result of both improved diagnostic techniques and longer survival due to better treatment approaches. However, it is still a challenging situation occasioned by the poor responses to different standard therapies, representing an unmet medical need. Determining the molecular profile may be clinically relevant in order to improve the outcome of our patients (pts).
Methods
This is an observational retrospective study including BC-pts who had undergone surgery of BCBM in Hospital Clinic (Barcelona, Spain) between January 2000 and December 2017. RNA was isolated from FFPE tumor tissue and the expression of 55 BC-related genes was assessed on the nCounter. Median progression free survival (mPFS) and overall survival (mOS) were calculated using the Kaplan-Meier method. The association of the expression of each gene with mPFS was evaluated using univariate Cox-models. The same gene expression assay was tested BCBM-paired primary tumor samples.
Results
20 pts with resected BMBC were included. Median age at diagnosis of BCBM was 57.8years (y). mOS from diagnosis of BCBM was 20.22 months (range, 0.67-64.50months). The intrinsic subtype distribution was 45% Basal-like, 20% HER2-enriched (HER2-E), 10% Luminal A, 20% Luminal B and 5% Normal-like. High expression of ESR1and PGR (determined as above the median) and low expression of MKI67were related with better mOS (p = 0.008, p = 0.038 and p = 0.0165). 9 matched-paired samples of primary BC and BCBM were analyzed and 4 (44.4%) PAM50 discordances (2 Luminal B shifted to Luminal A, 1 Normal-like to Basal-like and 1 HER2-E to Luminal B) were observed. Finally, down-regulation of CD8Aand PDL1expression between primary and BCBM (p = 0.0234 and p = 0.0367, respectively) was observed.
Conclusions
Non-luminal intrinsic subtypes are more prevalent in resected BCBM, and gene expression might predict OS. Our data suggest that BCBM can elude the immune surveillance through downregulation of immune genes leading to an immunosuppressed environment. Our analysis shows the value of analyzing gene expression both by cancer subtype and metastatic origin, but further characterization is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.
Funding
Fundación Científica Asociación Española Contra el Cáncer (PRÁCTICAS AECC CURSO ACADÉMICO 2018 to M.M-L).
Disclosure
M. Vidal: Speaker Bureau / Expert testimony: Roche; Speaker Bureau / Expert testimony: Daiichi Sankyo; Speaker Bureau / Expert testimony: Novartis. M. Muñoz: Travel / Accommodation / Expenses: Roche. A. Prat: Advisory / Consultancy: Nanostring Tech. All other authors have declared no conflicts of interest.
Resources from the same session
5063 - Does Nutritional Status Affect Treatment Tolarability, Response and Survival in Metastatic Gastric Cancer Patients? Results of Prospective Multicenter Study
Presenter: Senem Karabulut
Session: Poster Display session 2
Resources:
Abstract
2717 - Ramucirumab use in patients with Advanced Gastric Cancer (AGC) or gastro-oesophageal junction (GEJ) adenocarcinoma in Spain: RAMIS observational study
Presenter: Federico Longo Munoz
Session: Poster Display session 2
Resources:
Abstract
3187 - Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor: Exploratory analysis in the patients who were enrolled in JCOG0705/KGCA01 phase III trial (REGATTA) and could continue chemotherapy
Presenter: Takaki Yoshikawa
Session: Poster Display session 2
Resources:
Abstract
4765 - A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab based therapy
Presenter: Qian Li
Session: Poster Display session 2
Resources:
Abstract
3500 - Randomised phase 2 trial of first-line docetaxel, carboplatin, capecitabine (CTX) and epirubicin, oxaliplatin, capecitabine (EOX) in advanced esophagogastric adenocarcinoma (SEED)
Presenter: Peter Petersen
Session: Poster Display session 2
Resources:
Abstract
5197 - Ramucirumab in the treatment of refractory metastatic gastric cancer: results from the RamSelGa trial.
Presenter: Alexey Tryakin
Session: Poster Display session 2
Resources:
Abstract
2011 - Regorafenib in combination with Paclitaxel for beyond first-line treatment of advanced esophagogastric cancer (REPEAT): a phase Ib trial with expansion cohort
Presenter: Mohammed Khurshed
Session: Poster Display session 2
Resources:
Abstract
2117 - The relationship between the survival and fixed dosing of S-1 in advanced gastric cancer patients by pooled analysis using individual data from four Japanese randomized phase III trials
Presenter: Wataru Ichikawa
Session: Poster Display session 2
Resources:
Abstract
2669 - A Phase 1b Study of Oraxol in Combination with Ramucirumab in Patients with Gastric or Esophageal Cancers who failed previous chemotherapy
Presenter: Ming Huang Chen
Session: Poster Display session 2
Resources:
Abstract
3240 - Efficacy and safety of trifluridine/tipiracil (FTD/TPI) in European patients with heavily pretreated metastatic gastric cancer (mGC): an analysis of the TAGS study
Presenter: Maria Alsina
Session: Poster Display session 2
Resources:
Abstract